Evolent Health (EVH) In Sale Talks After Inbound Interest - Reuters
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Truist Securities Reiterates Buy Rating on Evolent Health (EVH)
August 23, 2024 7:02 AM EDTTruist Securities analyst Jailendra Singh reiterated a Buy rating and $33.00 price target on Evolent Health (NYSE: EVH).
The analyst comments "Bottom Line. M&A discussions related to EVH, whether in part of whole, is not a foreign discussion to the company. However, we... More
Piper Sandler Reiterates Overweight Rating on Evolent Health (EVH)
August 22, 2024 3:59 PM EDTPiper Sandler analyst Jessica Tassan reiterated an Overweight rating and $38.00 price target on Evolent Health (NYSE: EVH).
The analyst comments "Reuters reports that EVH is weighing sale, following takeover interest. The publication states that EVH has received initial offers and that potential acquirers could include PE firms or ELV (not covered) in combination with a PE partner. Our thoughts on today's news. 1. EVH is defining and dominating the market for value-based specialty care management. This is a $732B TAM which we define our white paper on the space here. 2. EVH has assembled best-in-class... More
BTIG Reiterates Buy Rating on Evolent Health (EVH)
August 22, 2024 3:57 PM EDTBTIG analyst David Larsen reiterated a Buy rating and $45.00 price target on Evolent Health (NYSE: EVH)
The analyst comments "Shares of EVH are trading up due to an article in Reuters, stating that several private equity firms, and at least one large health plan, are in discussions to potentially acquire EVH. The press report highlights that a process started after EVH received in-bound... More
